All In Biotech

Drug Trial Radar · NCT06510504

Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

370

Actual

Start

Aug 6, 2024

Primary completion

Sep 11, 2025

Study completion Sep 19, 2025

Sponsor

Lead sponsor
Bionomics LimitedIndustry
Sponsor type
Industry
First posted
Jul 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.

Conditions

  • Social Anxiety Disorder

Interventions

  • 225 mg BNC210Drug

    225 mg BNC210

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking ChallengeTime frame: Assessed over a single visit: On the treatment day at Baseline (approximately 5 minutes pre-dose) and during the Public Speaking Challenge Performance Phase conducted at 65 to 70 minutes post-dose (following the Anticipation Phase that started at 60 min).

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • AFFIRM-1 Study Site

    Encino, California

  • AFFIRM-1 Study Site

    La Jolla, California

  • AFFIRM-1 Study Site

    Los Angeles, California

  • AFFIRM-1 Study Site

    Oceanside, California

  • AFFIRM-1 Study Site

    San Diego, California

  • AFFIRM-1 Study Site

    San Jose, California

  • AFFIRM-1 Study Site

    Sherman Oaks, California

  • AFFIRM-1 Study Site

    Temecula, California

  • AFFIRM-1 Study Site

    Jacksonville, Florida

  • AFFIRM-1 Study Site

    Lauderhill, Florida

  • AFFIRM-1 Study Site

    Miami Lakes, Florida

  • AFFIRM-1 Study Site

    Orlando, Florida

  • AFFIRM-1 Study Site

    Tampa, Florida

  • AFFIRM-1 Study Site

    Decatur, Georgia

  • AFFIRM-1 Study Site

    Boston, Massachusetts

  • AFFIRM-1 Study Site

    Boston, Massachusetts

  • AFFIRM-1 Study Site

    Princeton, New Jersey

  • AFFIRM-1 Study Site

    Brooklyn, New York

  • AFFIRM-1 Study Site

    Charlotte, North Carolina

  • AFFIRM-1 Study Site

    Media, Pennsylvania

  • AFFIRM-1 Study Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.